Axolabs (Nuvisan)

Kulmbach, DE
Oligonucleotide
Program data pending ClinicalTrials.gov matching · Last scored 2026-03-15
60.5
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ○ Press

Quick Facts: Axolabs (Nuvisan)

Signal Score
60.5/100 (as of 2026-03-15)
Quality Compliance
Assessment pending
Headquarters
Kulmbach, DE
Modalities
Oligonucleotide
Active CGT Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CGT manufacturing intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesOligonucleotide
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 68.0
Parent company: Nuvisan
Financial assessment: 68.0/100
Source: SEC EDGAR, press monitoring
Subsidiary of Nuvisan
SEC FilingsParent: Nuvisan
Parent company: Nuvisan
Financial assessment: 68.0/100
Capacity 53.0
1 CGT manufacturing site: Kulmbach, DE
Modalities: Oligonucleotide
Capacity assessment: 53.0/100
Sites: Kulmbach, DE
Source: SEC EDGAR, press monitoring, company profiles
1 CGT manufacturing site
1 CGT manufacturing site: Kulmbach, DE
Modalities: Oligonucleotide
Capacity assessment: 53.0/100
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Oligonucleotide CDMOs →